MX360359B - Incrementadores de linea celular de produccion. - Google Patents
Incrementadores de linea celular de produccion.Info
- Publication number
- MX360359B MX360359B MX2014014630A MX2014014630A MX360359B MX 360359 B MX360359 B MX 360359B MX 2014014630 A MX2014014630 A MX 2014014630A MX 2014014630 A MX2014014630 A MX 2014014630A MX 360359 B MX360359 B MX 360359B
- Authority
- MX
- Mexico
- Prior art keywords
- production cell
- cell
- edem2
- cell line
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2477—Hemicellulases not provided in a preceding group
- C12N9/2488—Mannanases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Cell Biology (AREA)
Abstract
La presente invención se refiere al descubrimiento de la expresión ectópica de EDEM2 en una célula de producción para incrementar el rendimiento de una proteína de subunidad múltiple útil. Por lo tanto, la presente invención proporciona líneas de célula de producción, tal como la célula de producción biofarmacéutica de mamífero canónica - la célula CHO, que contiene los polinucleótidos recombinantes que codifican EDEM2. También se describe una célula de producción que contiene tanto un polinucleótido que codifica EDEM2, así como un polinucleótido que codifica XBP1. Se describen tituladores mejorados de anticuerpos producidos a través de estas líneas de células, así como las densidades de célula mejoradas logradas a través de estas células en el cultivo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261652549P | 2012-05-29 | 2012-05-29 | |
US13/904,587 US9079954B2 (en) | 2012-05-29 | 2013-05-29 | Production cell line enhancers |
PCT/US2013/043116 WO2013181253A1 (en) | 2012-05-29 | 2013-05-29 | Production cell line enhancers |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014014630A MX2014014630A (es) | 2015-02-12 |
MX360359B true MX360359B (es) | 2018-10-30 |
Family
ID=49670701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014014630A MX360359B (es) | 2012-05-29 | 2013-05-29 | Incrementadores de linea celular de produccion. |
Country Status (21)
Country | Link |
---|---|
US (9) | US9079954B2 (es) |
EP (3) | EP3564262A1 (es) |
JP (5) | JP6298455B2 (es) |
KR (4) | KR102663134B1 (es) |
CN (2) | CN104350068B (es) |
AU (4) | AU2013267525B2 (es) |
BR (1) | BR112014029095A2 (es) |
CA (1) | CA2873131A1 (es) |
DK (1) | DK2875047T3 (es) |
EA (2) | EA201792213A1 (es) |
ES (1) | ES2940900T3 (es) |
FI (1) | FI2875047T3 (es) |
HK (1) | HK1205137A1 (es) |
HU (1) | HUE061479T2 (es) |
IL (3) | IL235573B (es) |
MX (1) | MX360359B (es) |
PL (1) | PL2875047T3 (es) |
SG (2) | SG11201407652RA (es) |
TW (2) | TW201823460A (es) |
WO (1) | WO2013181253A1 (es) |
ZA (1) | ZA201408289B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201823460A (zh) | 2012-05-29 | 2018-07-01 | 美商再生元醫藥公司 | 生產細胞株增強子 |
AU2017253240B2 (en) | 2016-04-20 | 2024-07-04 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
SG11201807885PA (en) | 2016-04-20 | 2018-10-30 | Regeneron Pharma | Compositions and methods for making antibodies based on use of expression-enhancing loci |
US10995152B2 (en) | 2016-10-26 | 2021-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
CN109937034B (zh) | 2016-11-21 | 2022-09-16 | 济世-伊沃泰克生物制品有限公司 | 阿柏西普制剂及其用途 |
EP3668985B1 (en) | 2017-08-17 | 2021-06-16 | Just-Evotec Biologics, Inc. | Method of purifying glycosylated protein from host cell galectins and other contaminants |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL156910A0 (en) | 2001-01-16 | 2004-02-08 | Regeneron Pharma | Isolating cells expressing secreted proteins |
WO2003101189A1 (en) | 2002-05-29 | 2003-12-11 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
JP2006515163A (ja) | 2002-08-30 | 2006-05-25 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Xbp−1活性を調整するための方法および組成物 |
US20050106222A1 (en) * | 2003-06-11 | 2005-05-19 | Ailor Eric N. | Method to increase protein production in culture |
US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
EP1758929A4 (en) * | 2004-03-31 | 2009-08-05 | Centocor Inc | METHODS FOR ALTERING PROTEIN PRODUCTION RATES |
HUE029170T2 (en) | 2004-07-20 | 2017-03-28 | Genentech Inc | Preparations and methods for the use of angiopoietin-like protein 4 |
ES2653843T3 (es) | 2004-09-02 | 2018-02-09 | Wyeth Llc | Sistemas y procedimientos de producción de proteínas |
JP2008513465A (ja) * | 2004-09-15 | 2008-05-01 | ザ プレジデント アンド フェロウズ オブ ハーバード カレッジ | 肥満及び糖尿病の治療におけるerストレス低減 |
EP1964922A1 (en) * | 2007-03-02 | 2008-09-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | Improvement of protein production |
US8546126B2 (en) | 2007-03-21 | 2013-10-01 | Danisco Us Inc. | Over expression of foldases and chaperones improves protein production |
US7771997B2 (en) | 2007-06-04 | 2010-08-10 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
WO2009020802A2 (en) * | 2007-08-03 | 2009-02-12 | Eli Lilly And Company | Treatment for obesity |
PE20091163A1 (es) * | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
WO2009062789A1 (en) | 2007-11-13 | 2009-05-22 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Improving the secretory capacity in host cells |
US20090247609A1 (en) * | 2007-12-20 | 2009-10-01 | Hitto Kaufmann | Sm-protein based secretion engineering |
JP5694924B2 (ja) | 2008-05-28 | 2015-04-01 | バイエル・ヘルスケア・エルエルシー | HBx発現哺乳動物細胞における組み換えタンパク質の製造方法およびその組成物 |
WO2010008860A1 (en) | 2008-06-23 | 2010-01-21 | President And Fellows Of Harvard College | Modulation of neurodegenerative disease by modulating xbp-1 activity |
US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
GB0902180D0 (en) * | 2009-02-10 | 2009-03-25 | Ucb Pharma Sa | Method for producing protein |
US8722046B2 (en) * | 2009-04-08 | 2014-05-13 | The United States Of America As Represented By The Secretary Of The Army | Human monoclonal antibodies protective against bubonic plague |
TWI513818B (zh) | 2009-06-02 | 2015-12-21 | Regeneron Pharma | 岩藻糖基化(fucosylation)-缺乏之細胞 |
JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
JO3274B1 (ar) * | 2009-12-24 | 2018-09-16 | Regeneron Pharma | أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري |
JO3340B1 (ar) * | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
TW201823460A (zh) | 2012-05-29 | 2018-07-01 | 美商再生元醫藥公司 | 生產細胞株增強子 |
CN110787285A (zh) | 2012-11-05 | 2020-02-14 | 达纳-法伯癌症研究所股份有限公司 | Xbp1、cd138和cs1肽、包括所述肽的药物组合物及使用所述肽和组合物的方法 |
-
2013
- 2013-05-28 TW TW107107833A patent/TW201823460A/zh unknown
- 2013-05-28 TW TW102118721A patent/TWI641687B/zh active
- 2013-05-29 ES ES13729169T patent/ES2940900T3/es active Active
- 2013-05-29 HU HUE13729169A patent/HUE061479T2/hu unknown
- 2013-05-29 EA EA201792213A patent/EA201792213A1/ru unknown
- 2013-05-29 PL PL13729169.6T patent/PL2875047T3/pl unknown
- 2013-05-29 EP EP19177521.2A patent/EP3564262A1/en not_active Withdrawn
- 2013-05-29 BR BR112014029095A patent/BR112014029095A2/pt not_active Application Discontinuation
- 2013-05-29 KR KR1020237014681A patent/KR102663134B1/ko active IP Right Grant
- 2013-05-29 EP EP22214230.9A patent/EP4219546A3/en active Pending
- 2013-05-29 MX MX2014014630A patent/MX360359B/es active IP Right Grant
- 2013-05-29 SG SG11201407652RA patent/SG11201407652RA/en unknown
- 2013-05-29 EA EA201492242A patent/EA028790B1/ru not_active IP Right Cessation
- 2013-05-29 SG SG10201606654XA patent/SG10201606654XA/en unknown
- 2013-05-29 AU AU2013267525A patent/AU2013267525B2/en active Active
- 2013-05-29 CN CN201380028164.9A patent/CN104350068B/zh active Active
- 2013-05-29 KR KR1020147033930A patent/KR102126210B1/ko active IP Right Grant
- 2013-05-29 KR KR1020217043208A patent/KR102528950B1/ko active IP Right Grant
- 2013-05-29 CN CN201911104558.3A patent/CN110835624A/zh active Pending
- 2013-05-29 DK DK13729169.6T patent/DK2875047T3/da active
- 2013-05-29 EP EP13729169.6A patent/EP2875047B1/en active Active
- 2013-05-29 FI FIEP13729169.6T patent/FI2875047T3/fi active
- 2013-05-29 JP JP2015515154A patent/JP6298455B2/ja active Active
- 2013-05-29 US US13/904,587 patent/US9079954B2/en active Active
- 2013-05-29 KR KR1020207017417A patent/KR102346867B1/ko active IP Right Grant
- 2013-05-29 CA CA2873131A patent/CA2873131A1/en active Pending
- 2013-05-29 WO PCT/US2013/043116 patent/WO2013181253A1/en active Application Filing
-
2014
- 2014-11-09 IL IL235573A patent/IL235573B/en active IP Right Grant
- 2014-11-12 ZA ZA2014/08289A patent/ZA201408289B/en unknown
- 2014-11-26 US US14/555,220 patent/US9382315B2/en active Active
-
2015
- 2015-06-11 US US14/737,090 patent/US10227401B2/en active Active
- 2015-06-12 HK HK15105590.6A patent/HK1205137A1/xx unknown
- 2015-06-29 US US14/754,146 patent/US9228012B2/en active Active
- 2015-06-29 US US14/754,112 patent/US9193786B2/en active Active
-
2016
- 2016-07-01 US US15/201,104 patent/US9688751B2/en not_active Ceased
-
2017
- 2017-06-16 US US15/624,982 patent/US10351622B2/en active Active
-
2018
- 2018-02-14 AU AU2018201094A patent/AU2018201094B2/en active Active
- 2018-02-23 JP JP2018030324A patent/JP6622334B2/ja active Active
-
2019
- 2019-04-07 IL IL265867A patent/IL265867A/en unknown
- 2019-04-17 US US16/387,134 patent/USRE48651E1/en active Active
- 2019-05-21 US US16/417,792 patent/US10611831B2/en active Active
- 2019-05-30 AU AU2019203780A patent/AU2019203780B2/en active Active
- 2019-11-21 JP JP2019210124A patent/JP7037535B2/ja active Active
-
2021
- 2021-01-03 IL IL279922A patent/IL279922A/en unknown
- 2021-10-01 AU AU2021240303A patent/AU2021240303A1/en active Pending
- 2021-12-27 JP JP2021212131A patent/JP7382383B2/ja active Active
-
2023
- 2023-08-22 JP JP2023134346A patent/JP2023153268A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014014630A (es) | Incrementadores de linea celular de produccion. | |
EP4148121A3 (en) | Cell-controlled perfusion in continuous culture | |
MX337985B (es) | Polipeptidos que tienen actividad de celobiohidrolasa y polinucleotidos que codifican los mismos. | |
MX337919B (es) | Polipeptidos que tienen actividad de celobiohidrolasa y polinucleotidos que codifican los mismos. | |
MX337913B (es) | Polipeptidos que tienen actividad celobiohidrolasa y polinucleotidos que codifican los mismos. | |
IN2015DN01606A (es) | ||
MX353710B (es) | Polipeptidos que tienen actividad de lisozima y polinucleotidos que los codifican. | |
EA201590599A1 (ru) | Способ получения 1-кестозы | |
MY181513A (en) | Cell culture compositions and methods for polypeptide production | |
MX351850B (es) | Metodo para el cribado de alfa-amilasas. | |
WO2013076144A3 (en) | Microorganism strains for the production of 2,3-butanediol | |
GB2527254A (en) | Benzylisoquinoline alkaloids (BIA) Producing microbes, and methods of making and using the same | |
MX2012006096A (es) | Polipeptidos que tienen actividad glucoamilasa y polinucleotidos que codifican para los mismos. | |
EA201300074A1 (ru) | Способ получения представляющего интерес соединения | |
EA201490216A1 (ru) | Варианты альфа-амилазы и кодирующие их полинуклеотиды | |
SG10201809452RA (en) | Cell culture compositions with antioxidants and methods for polypeptide production | |
MX2014001594A (es) | Polipeptidos que tienen actividad de celulasa y polinucleotidos que los codifican. | |
MX2012006095A (es) | Polipeptidos que tienen actividad glucoamilasa y polinucleotidos que codifican para los mismos. | |
IN2015DN02630A (es) | ||
MX349517B (es) | Polipeptidos que tienen actividad de proteasa y polinucleotidos que codifican los mismos. | |
MX2015011781A (es) | Medio de cultivo celular y metodos de produccion de anticuerpos. | |
MX2018004580A (es) | Metodo para producir proteina de fusion con dominio fc de igg. | |
MX350391B (es) | Polipeptidos que poseen actividad proteasa y polinucleotidos que los codifican. | |
EA200900984A1 (ru) | Улучшение клеточного роста | |
MX2015007775A (es) | Polipeptidos que poseen actividad proteasa y polinucleotidos que los codifican. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |